EVENTS | VIEW CALENDAR
NIH Human Microbiome Project researchers publish first genomic collection of human microbes
BETHESDA, Md.—Making great strides in its goal to better understand the microorganisms that reside in the human body, the Human Microbiome Project (HMP), an extension of the Human Genome Project, recently published an analysis of 178 genomes from microbes that live in or on the human body. Publishing their findings in the May 21 issue of the journal Science, the researchers describe their discovery of novel genes and proteins that serve functions in human health and disease, adding a new level of understanding to what is known about the complexity and diversity of these organisms.
Launched in 2008 as part of the National Institutes of Health (NIH) Common Fund's Roadmap for Medical Research, the HMP is a $157 million, five-year effort that seeks to implement a series of increasingly complicated studies that reveal the interactive role of the microbiome in human health, a topic that is not currently well understood.
"This initial work lays the foundation for this ambitious project and is critical for understanding the role that the microbiome plays in human health and disease," said NIH Director Dr. Francis S. Collins in a statement. "We are only at the very beginning of a fascinating voyage that will transform how we diagnose, treat and ultimately, prevent many health conditions."
The initial stage of the HMP, which includes the current study, focused on bacteria. So far, the effort has allowed researchers to create a framework for data resources and standards. In addition, the project is supporting the development of innovative technologies and computational tools, coordination of data analysis, and an examination of some of the ethical, legal and social implications of human microbiome research.
The 178 microbial genomes in the report launch the HMP reference collection that eventually will total approximately 900 microbial genomes of bacteria, viruses and fungi. These data will then be used by HMP researchers to characterize the microbial communities found in samples taken from healthy human volunteers, and later, those with specific illnesses. Samples are currently being collected for HMP from the digestive tract, the mouth, the skin, the nose and the vagina.
Researchers also conducted a preliminary survey to gain insights into the function of some of the newly identified genes and proteins unique to individual microbial strains. For instance, researchers found previously unknown proteins produced by bacteria that live in the stomach that may cause gastric ulceration, a hole in the stomach lining. In addition, they found a small number of newly identified novel proteins associated with how sugars and amino acids are metabolized.
Researchers also evaluated the microbial diversity present in the HMP reference collection. For example, they found 29,693 previously undiscovered, unique proteins in the reference collection—more proteins than there are estimated genes in the human genome. They compared their results to the same number of previously sequenced microbial genomes randomly selected from public databases. In the microbial genome from public databases, they found 14,064 novel proteins. These data, the researchers say, suggest that the HMP reference collection has nearly twice the amount of microbial diversity than is represented by microbial genomes already in public databases.
One of the primary goals of the HMP reference collection is to expand researchers' ability to interpret data from metagenomic studies. Comparing metagenomic sequence data with genomes in the reference collection can help researchers determine whether they are novel or already existing sequences.
To evaluate whether the reference collection of genomes was meeting the goal above, the researchers compared 16.8 million microbial sequences found in public databases to the genome sequences in the HMP reference collection. They found that 62 genomes in the reference collection showed similarity with 11.3 million microbial sequences in public databases and 6.9 million of these—about 41 percent—correspond with genome sequences in the reference collection.
This analysis demonstrates that genomes sequenced as part of the reference collection add directly to an understanding of the human microbiome. However, researchers cautioned that at least one-third of the metagenomic sequences are still not represented by any genome in the reference collection and that this analysis focused only on the gastrointestinal tract. The authors added that additional genomes likely exist in other body sites and the completion of the reference collection should address many of the remaining organisms not accounted for in this analysis.
With funding from the HMP, several large-scale sequencing centers performed genome sequencing work for the project: The Human Genome Sequencing Center at Baylor College of Medicine in Houston; the Washington University Genome Sequencing Center at Washington University School of Medicine in St. Louis; the J. Craig Venter Institute in Rockville, Md.; and the Broad Sequencing Platform at the Broad Institute of MIT/ Harvard in Cambridge, Mass.
According to the NIH, future genome sequencing and human microbiome studies will capture information about more complex microbes and viruses.
"Although this is only the first step in making HMP medically useful, we already have learned surprising things about the diversity and complexity of the microorganisms that live in and on our body," said Dr. Jane Peterson, associate director of the National Human Genome Research Institute (NHGRI) Division of Extramural Research and a leader of the HMP effort, in a statement. "The next stages of this coordinated study will begin to associate the presence or absence of specific micro-organisms with various states of health and illness."
The HMP is currently funding pilot demonstration projects by researchers that will sample the microbiomes of healthy volunteers and volunteers with specific diseases over the next year. This will allow researchers to study changes in the microbiome at particular body sites in healthy controls compared to patients affected by diseases. These studies will use samples collected from the digestive tract, the mouth, the skin, the nose, the vagina, the blood and the male urethra.